BOSTON ( TheStreet) -- Welcome to Biotech Stock Live Chat: Hurricane Sandy edition.

First, let me say I hope everyone is safe and as comfortable as possible following a crazy day and night. Here just north and west of Boston, we managed to get through relatively unscathed but I know a lot of people without power or with significant damage to their homes. My sympathies.

U.S. stock markets are closed for a second straight day due to the storm, so while we're all sitting around (or taking a break from Sandy clean up) let's spend an hour or so talking biotech stocks and biotech investing.

The floor is yours. I'm happy to discuss Amarin ( AMRN - Get Report) and the outlook for the pending launch of its prescription fish-oil pill Vascepa. I know many of you are very bullish on Amarin's future so make your case here in the live blog.

Obesity drug stocks -- Vivus ( VVUS - Get Report), Arena Pharmaceuticals ( ARNA - Get Report) and Orexigen Therapeutics ( OREX) -- are always a good topic.

Biotech earnings season has been interrupted due to the storm but we will get reports this week from Onyx Pharmaceuticals ( ONNXX) and Medivation ( MDVN), giving us the first peek at new cancer drug launches. Also scheduled to report: Vertex Pharmaceuticals ( VRTX), Dendreon ( DNDN), Spectrum Pharmaceuticals ( SPPI - Get Report) and Incyte ( INCY - Get Report). Let's discuss.

Sarepta Therapeutics ( SRPT - Get Report): Why is the stock down so much since early October? What are the chances for eteplirsen accelerated approval?

Let's chat about these stocks or any other biotech investing question you might have. Thanks for participating.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.